Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.41 |
| ▸ | UGCG | Q16739 | 7/20 | 0.39 |
| ▸ | IDH1 | O75874 | 3/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RBP4 | P02753 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL1635110 | 1.00 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1UGCGIDH1LRRK2 | |
| SCHEMBL1635528 | 0.96 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1UGCGIDH1LRRK2 | |
| SCHEMBL14538447 | 0.96 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1UGCGIDH1LRRK2 | |
| SCHEMBL1635320 | 0.96 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1UGCGIDH1LRRK2 | |
| Formic Acid SCHEMBL1636026 | 0.93 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1UGCGIDH1LRRK2 | |
| Formic Acid SCHEMBL1634914 | 0.93 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1UGCGIDH1LRRK2 | |
| SCHEMBL1634948 | 0.89 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1UGCGIDH1LRRK2 | |
| SCHEMBL1635333 | 0.89 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1UGCGIDH1LRRK2 | |
| SCHEMBL1636023 | 0.89 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1UGCGIDH1LRRK2 | |
| Formic Acid SCHEMBL1572911 | 0.80 | CCNC (0.39) | UGCGMAPTRBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932248-B2 | 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity | MEMORY PHARMACEUTICALS CORPORATION (US) | 2011-04-26 | — | — | US | claimed |
| US-20070135417-A1 | 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity | MEMORY PHARMACEUTICALS CORPORATION | 2007-06-14 | — | — | US | claimed |
| US-7932248-B2 | 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity | MEMORY PHARMACEUTICALS CORPORATION (US) | 2011-04-26 | — | — | US | disclosed |
| US-20070135417-A1 | 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity | MEMORY PHARMACEUTICALS CORPORATION | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135417-A1 | 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity | CHRNA7, CHRNA5, CHRNA3 | HSP90AA1 2826/4885HSP90AB1 2306/4885UGCG 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.